XiJian Technologies Secures Tens of Millions in Pre-A+ Funding to Build a Global-Leading Soft Tissue Biomechanical Imaging Platform

VCBeat has learned that recently,Beijing Xijian Technology Co., Ltd. (hereinafter referred to as “Xijian Technology”）Announced the completion of a pre-A+ financing round worth tens of millions of yuan, led byYizhuang CapitalLead Investor,Ruihua CapitalCo-investment, Existing ShareholdersYuanhui ChuangyiContinue to increase investment,Index CapitalServed as the exclusive financial advisor. The funds from this round of financing will be used for product R&D, team expansion, and marketing efforts. Established just two years ago, Xijian Technology has successfully completed three rounds of financing.

Beijing Xijian Technology Co., Ltd. builds upon more than a decade of research foundation in the characterization of human soft tissue mechanics from the Laboratory for Biomaterials and Soft Material Mechanics at Tsinghua University, dedicated to advancing the industrialization of innovative technologies in human biomechanical imaging and establishing a globally leading platform for mechanical imaging of human soft tissues.The company focuses on blue-ocean, high-demand markets in health sectors such as sports rehabilitation, aesthetic dermatology, and the diagnosis and treatment of major diseases. It provides the industry with world-leading biomechanical imaging equipment for human soft tissues (e.g., skeletal muscle, skin, tumors, blood vessels, and core organs) and co-builds an intervention ecosystem based on human biomechanical imaging.

To date, the company has two global innovative products undergoing medical device registration. In addition, its series of soft-material bionic phantoms has entered the commercialization stage. Notably, the world’s first portable integrated imaging system for skeletal muscle structure and mechanical properties enables in vivo quantitative assessment of both skeletal muscle structure and mechanical performance. It provides effective solutions to world-class challenges, including the strong anisotropy of tendons and muscles, the active stress levels of contracting muscles, and stress measurements in loaded tendons at the megapascal level. The system delivers stable and reliable measurement results, with significant application potential in digital orthopedics, digital rehabilitation, and professional sports.

Xijian Technology Globally Debuts Portable Integrated Imager for Skeletal Muscle Structure and Mechanical Properties

In the serious medical sector, the company adheres to a clinical demand-driven approach, combining innovative technologies with clinical benefits to develop and promote integrated products for medical practice, education, and research. In the fields of orthopedics and sports rehabilitation, Beijing Xijian Technology Co., Ltd. has received support from the “Innovation Fund” key projects of the National Clinical Research Center for Orthopedics and Sports Rehabilitation. In the future, the company will rely on the integrated innovation ecosystem of “medicine, research, government, enterprise, and capital” established by the National Clinical Research Center, supported by a collaborative innovation system covering more than 1,200 hospitals across China, to achieve leapfrog development from specialization to industrialization and from innovation to widespread adoption.

Furthermore, the company has established in-depth collaborations with top-tier medical platforms and research institutions, including the Microsurgery Alliance, the Chinese PLA General Hospital, Peking University Third Hospital, Beijing Friendship Hospital, Beijing Tsinghua Changgung Hospital, and Beijing Sport University, to jointly advance the deep exploration and promotion of clinical indications for biomechanical imaging. Clinical studies addressing conditions such as knee osteoarthritis, adolescent idiopathic scoliosis, lymphedema, diabetic foot, and muscle fatigue are currently progressing efficiently.

The company is also actively expanding its presence in consumer sectors such as anti-aging medical aesthetics.Continuously empowering scientific medical aesthetics, digital medical aesthetics, and standardized training. On October 22, 2023, at the globally renowned academic conference on medical aesthetics—the AMWC (Aesthetic & Anti-aging Medicine World Congress)—Beijing Xijian Technology Co., Ltd. made its debut with its dermatological and medical aesthetic-related products, receiving enthusiastic and positive responses.

Xijian Technology Unveils Dermatological Aesthetic Products at the 2023 World Congress on Anti-Aging Medicine

Leveraging its profound and solid technical expertise and efficient medical-engineering cross-disciplinary iteration, Beijing Xijian Technology Co., Ltd. has completed three rounds of financing within just two years of its establishment, continuously attracting numerous prominent investors to accelerate its growth.

To date, the company has obtained qualifications such as National Technology-Based SME and Zhongguancun High-Tech Enterprise, holds more than ten granted core patents, and was recognized as one of the “2023 EY-Fudan Most Promising Companies” in September 2023. The company’s core team comprises graduates from top domestic and international universities, including Tsinghua University, Peking University, Beihang University, Beijing Sport University, Huazhong University of Science and Technology, and Cornell University. Their industry expertise spans investment and financing, corporate management, product definition, quality management, and marketing. Moving forward, the team will continue to drive the industrialization of the company’s platform technology for human biomechanical imaging, continuously empower the health and consumer industries, firmly establish a globally leading platform for biomechanical imaging of human soft tissues, and collaborate with strategic partners to develop an intervention ecosystem based on human biomechanical imaging.

Beijing Xijian Technology Co., Ltd. Has Obtained Multiple Qualification Certifications and Corporate Awards

The National Clinical Research Center for Orthopedics, Sports Medicine, and Rehabilitation was officially approved for establishment in May 2019 by the Ministry of Science and Technology, the National Health Commission, the National Medical Products Administration, and the Logistics Support Department of the Central Military Commission. It is currently the leading institution in China in the fields of orthopedics, sports medicine, and rehabilitation.The Only National-LevelClinical Medical Research Platform. Relying on the Chinese PLA General Hospital as its supporting institution, the Center bears the important mission and task of strengthening the construction of a medical science and technology innovation system and creating a “new highland” for national clinical medicine and translational research. Currently, the National Clinical Medical Research Center has established an integrated innovation ecosystem encompassing “medicine, research, government, enterprise, and capital,” involving national functional agencies, national evaluation and testing institutions, local governments, industrial parks, research institutes, medical institutions, innovative enterprises, and capital institutions. It has built a full-lifecycle innovation support platform that integrates demand collection, innovative R&D, pilot production, product testing, clinical trials, registration and certification, clinical application, post-market evaluation, technology promotion, and scientific popularization, thereby exploring a new path for the development of innovative enterprises.

Yizhuang Capital (full name: “Yizhuang Equity Investment Private Fund Management (Beijing) Co., Ltd.”), established in September 2020, is the sole private fund management institution under Yizhuang Holdings Group, an industrial new city operator.Yizhuang Capital operates on market-oriented principles, focusing on hard-tech sectors such as medical devices and advanced manufacturing. It prioritizes investments in early- to mid-stage startups and commits to long-term partnership for mutual growth.To date, the company has cumulatively invested in more than ten projects.

Ruihua Capital’s business scope encompasses investments in the secondary equity market, private equity, private placements, private (trust) funds, and financial derivatives. Its equity investment strategy focuses on key sectors such as big health, new energy, and semiconductors. Upholding the Ruihua values of “Integrity, Excellence, Win-Win Cooperation, Long-Term Vision, and Ethical Practice,” the firm provides comprehensive value-added services to enterprises, serving as their long-term strategic partner.

Beijing Yuanhui Venture Capital Co., Ltd. (Yuanhui Chuangyi) was established in 2010. With a long-term perspective, it seeks out and partners with passionate entrepreneurs and innovative enterprises possessing hard-core technologies to foster mutual growth. Guided by the core principles of “Business for Good” and “Technology for the Benefit of Humanity,” it encourages companies to assume social responsibility. Through innovative redistribution of commercial returns, it continuously generates sustainable funding and empowerment for modern educational philanthropy. Yuanhui Chuangyi focuses on investments in hard-core technologies, prioritizing the upstream life sciences sector (medical devices/instruments, biological reagents, biomaterials, etc.) and the front-end ICT industry (semiconductors, core components, materials, and foundational software), while also maintaining a selective interest in technology projects such as new energy and intelligent manufacturing.